About Us
At Fagus Therapeutics, our mission is to confront the health challenges that come with ageing. With age, the likelihood of developing conditions like arthritis, osteoporosis, and diabetes climbs, diminishing our quality of life and exerting pressure on global healthcare systems.
To tackle this, we’ve adopted an innovative strategy that targets senescent cells – the culprits behind many age-related diseases. Our method uses targeted antibodies designed to recognise and attach to these cells, delivering a therapeutic agent that prompts them to undergo natural cell death. This approach holds the promise of lightening the load of age-related diseases on both individuals and healthcare services.
Our efforts are bolstered by a team of seasoned experts in ageing and cellular biology. These advisors – accomplished scientists and clinicians with a profound understanding of the ageing process – steer our strategic direction and research initiatives. Their invaluable expertise ensures our strategies are anchored in cutting-edge scientific research, poised to drive significant advancements in treating age-related conditions.
Dedicated to deepening our grasp on how to effectively target senescent cells, Fagus Therapeutics is committed to mitigating the effects of ageing on individuals and healthcare systems alike. Guided by our distinguished advisors, we’re pushing the boundaries of research into age-related diseases, working towards a future where ageing doesn’t necessarily equate to illness.